RPE65 and Leber congenital amaurosis: In 2017, the United States Food and Drug Administration (FDA) approved Voretigene Neparvovec (Luxturna), an adeno-associated virus (AAV) vector-based therapy for patients with biallelic RPE65 mutation-associated Leber congenital amaurosis (LCA).